ASH 2023 | Ascentage Pharma to Present Results from Three Cl

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Zhejiang , China , Shanghai , San Diego , California , United States , Australia , Nanfang , Guangdong , Beijing , Hong Kong , Qian Jiang , Hubei , Rockville , Henan , Suzhou , Jiangsu , Peking , Philadelphia , Pennsylvania , Chinese , Jianyong Li , Jianxiang Wang , Prnewswire Ascentage Pharma , Huafeng Wang , Elias Jabbour , Xiaojun Huang , Jie Jin , Keshu Zhou , Sikander Ailawadhi , Xiaoyuan Gong , Yifan Zhai , Liposome Mitoxantrone , Hagop Kantarjian , Hongsheng Zhou , Shuhong Shen , Ascentage Pharma , Gaixiang Xu , Zhejiang University School Of Medicine , Institute Of Hematology , Md Anderson Cancer Center , Nanfang Hospital Of Southern Medical University , Astrazeneca , Shanghai Children Medical Center , University People Hospital , Department Of Hematology Oncology , National Reimbursement Drug List , China National Medical Products Administration , Chinese Academy Of Medical Sciences , Shanghai Jiao Tong University School Of Medicine , Dana Farber Cancer Institute , American Society Of Hematology , Major National , American Society , Annual Meeting , Chief Medical Officer , Drug Candidates , Demonstrates Efficacy , Best Available Therapy , Tyrosine Kinase Inhibitor , Resistant Chronic Myeloid Leukemia Phase , Registrational Randomized Phase , Blood Diseases Hospital , Chinese Academy , Overcoming Ponatinib , Asciminib Resistance , Refractory Chronic Myeloid Leukemia , Pediatric Patients , Recurrent Acute Myeloid Leukemia , Shanghai Children , Medical Center , Shanghai Jiao Tong University School , Adult Patients , First Affiliated Hospital , Zhejiang University School , Based Therapy , Advanced Chronic Myeloid Leukemia , Southern Medical , Safety Results , Heavily Pretreated Chronic Lymphocytic Leukemia , Pool Analysis , Two Clinical , Cancer Hospital , Acute Myeloid , Myelodysplastic Syndrome , Novel Therapeutic Regimens , Refractory Multiple Myeloma , Immunoglobulin Light Chain , Amyloid Light Chain , Lymphocytic Leukemia , Pacific Time , Myeloid Leukemias , Investigational Therapies , Excluding Transplantation , Prospective Therapeutic Trials , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Pediatric Disease , Cancer Center , Mayo Clinic ,